Drug Resistance

Nisin Evaluated for Antibiotic-Resistant Infections Treatment

Published in Cancer Weekly, July 7th, 1997

AMBI Inc., Tarrytown, New York, announced results of a human study demonstrating that Nisin was successfully delivered orally, in tablet form, to the colon.

"The results of this study represent a major milestone in the development of nisin, which may have the potential to be the first peptide that can be taken orally as a treatment for a serious infectious disease of the colon," said George A. Digenis, Ph.D., University of Kentucky, who collaborated on the study design.

The study used radiolabeling technology in which images of the tablets were captured as they traveled intact through the stomach and the small intestine and then released nisin at the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-07-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry